Volume 31, Number 12—December 2025
Synopsis
Retrospective Multicenter Study of Human Granulocytic Anaplasmosis, France, 2012–2024
Victor Gerber
, Thomas Lemmet, Thomas Bonijoly, Baptiste Hoellinger, Anne Pachart, Amandine Woerly, Dominique De Briel, Emilie Talagrand-Reboul, Martin Martinot, Pierre Boyer, and Yves Hansmann
, Thomas Lemmet, Thomas Bonijoly, Baptiste Hoellinger, Anne Pachart, Amandine Woerly, Dominique De Briel, Emilie Talagrand-Reboul, Martin Martinot, Pierre Boyer, and Yves Hansmann
Table 3
Laboratory findings for 39 cases a retrospective multicenter study of human granulocytic anaplasmosis, France, 2012–2024*
| Laboratory findings | Value | Reference range |
|---|---|---|
| Thrombocytopenia, no. (%) | 37 (94.9) | |
| Median cells × 103/μL (range) |
59 (19–316) |
150–400 |
| Leucopenia, no. (%) | 23 (59.0) | |
| Median cells × 103/μL (range) |
3.2 (1.02–13.01) |
4.1–10.5 |
| Anemia | 8 (20.5) | |
| Median hemoglobin, g/dL (range) |
13.4 (8.8–15.8) |
13–18 |
| No cytopenia, no. (%) | 2 (5.1) | |
| Reactive lymphocytes, no. (%) |
7 (17.9) |
|
| Elevated liver enzymes, no. (%) | 26 (66.6) | |
| Median AST, IU/L (range) | 103 (24–509) | 13–40 |
| Median ALT, IU/L (range) |
80.5 (27–829) |
7–40 |
| Elevated creatinine, no. (%) | 7 (17.9) | |
| Median creatinine, μmol/L (range) |
82 (43–233) |
53–97 |
| Elevated CRP | 39 (100) | |
| Median CRP, mg/L (range) |
130 (10–286) |
0–5 |
| Rhabdomyolysis, no. (%) | 5 (12.8) | |
| Median CK, IU/l (range) |
106 (40–1,012) |
40–250 |
| Myelogram performed, no. (%) | 8 (20.5) | |
| Median HScore (range)† |
76 (19–208) |
NA |
| Anaplasma phagocytophilum testing, no. (%) | ||
| Positive blood smear with morulae | 8 (20.5) | NA |
| Positive IgM at diagnosis | 9 (23.1) | Cutoff 1:20 |
| Positive IgG at diagnosis | 7 (17.9) | Cutoff 1:64 |
| Other PCR positive, CSF | 1 (2.6) | NA |
| Tickborne disease co-infection, Lyme disease‡ | 1 (2.6) | NA |
*ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; CK, creatine kinase; CSF, cerebrospinal fluid; NA, not applicable. †A score used for determining reactive hemophagocytic syndrome. ‡Co-infection data are based on medical records; no further diagnostic details available.
Page created: December 04, 2025
Page updated: January 01, 2026
Page reviewed: January 01, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.